Providing a VOICE for Montana's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 2015
Meetings & Education
State & Federal Resources
National Professional Organizations
Off-Label Use Literature
Patient Advocacy Organizations
Become a Corporate Member
Industry News Archive
COVID-19 Featured Resources
Administration Withdraws Proposed Drug Rebate Rule
On July 11, the White House announced withdrawal of its
proposed drug rebate rule
that would have removed rebates from government drug plans.
“Based on careful analysis and thorough consideration, the President has decided to withdraw the rebate rule,” said White House spokesman Judd Deere. “The Trump administration is encouraged by continuing bipartisan conversations about legislation to reduce outrageous drug costs imposed on the American people, and President Trump will consider using any and all tools to ensure that prescription drug costs will continue to decline.”
The controversial proposed rule fueled a rift in the Administration with HHS Secretary Alex Azar supporting the curbing of drug rebates and other White House officials in opposition due to the potential for the proposal to increase Medicare spending by nearly $200 billion.
The proposed rule was considered central to the Administration's
drug pricing reform plan
. Withdrawal of the proposal likely signals an even greater focus by the Administration on its
proposed International Pricing Index Model for Medicare Part B Drugs
, which is currently undergoing review at the White House.